Phase 3 Multicenter Adult Double-Blind
Rezafungin For Injection (REZZAYO)
ReSPECT Phase 3 Adult ABMT Study
Study ID: CD101.IV.3.08
Study Title: Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases (IFD) in Adults Undergoing Allogeneic Blood and Marrow Transplant (ABMT)
ClinicalTrials.gov ID and Link: NCT04368559
Melinta has licensed US commercial rights to rezafungin from Mundipharma, which is the sponsor of this study.
Phase 1 Pediatric US Open-Label
(KIMYRSA and ORBACTIV)
Oritavancin 3-hr infusion
Study ID: TMC-ORI-11-01
Study Title: Phase 1 Pediatric US Open-Label: Dose-finding, Pharmacokinetics (PK), Safety and Tolerability Study in Pediatric Subjects with Suspected or Confirmed Bacterial Infections
ClinicalTrials.gov ID and Link: NCT02134301
Oritavancin 3-hr or 1-hr Infusion
Study ID: ML-ORI-201
Study Title: Randomized, Open-Label, Safety and Tolerability Study in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)
ClinicalTrials.gov ID and Link: NCT05599295
Phase I Pediatric Open-Label
Meropenem And Vaborbactam (VABOMERE)
TANGOKIDS
Study ID: Rempex 507
Study Title: Dose-finding, PK, Safety, and Tolerability Study of a Single Dose of Meropenem-Vaborbactam in Pediatric Subjects with Serious Bacterial Infections
ClinicalTrials.gov ID and Link: NCT02687906
or click here to access
our online form.
Report an Adverse Event or Quality Complaint
Call 1-844-MED-MLNT(+1 844-633-6568).
You may also report suspected
adverse events to the FDA
at 1-800-FDA-1088 or
https://www.fda.gov/medwatch
Scan
Access Melinta MedicalInformation Library
NEWR Call
1-844-med-mlnt(+1 844-633-6568)
to speak with a medical
information representative